Clinical Trial Search

Primary: Retention, Measured as the Number of HIV Exposure Events That Were Retained in Care at the 24 Week Follow-up Visit — 125; 157 HIV Exposure Events — p=<0.05

Primary: Number of Participants With Early Discontinuation From Randomized Human Immunodeficiency Virus Postexposure Prophylaxis (HIV PEP) — 10; 15 participants — p=0.2434

Primary: Medication Regimen Completion Rates — 57; 28; 15 participants

Primary: Evidence of Toxicity. Toxicity Was Measured as Any Adverse Event; Nausea, Vomiting, Diarrhea. Elevated Liver Function Tests. — 4; 4 adverse events

Primary: Blood Exposure — 1.9; 1.9 Number of Glove Pairs Used Per Razor Bla

Primary: Number of Adverse Event Occurrences — 38; 28; 28; 14 events

Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants

Primary: WHO Anthropometric Measure of Weight-for-Age Z-Score — -0.32; -0.80; -1.59; -0.29 Z-scores

Primary: Percentage of Participants With Unsolicited Systemic Adverse Event (AE) — 0; 0 percentage of participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 1; 1; 0; 0 Participants

Primary: Proportion of Participants Who Did Not Complete the 28-day PEP Regimen — 114 Participants

Primary: Tolerability and Safety of the Treatment. — 0; 0 participants

Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants

Primary: Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series…

Primary: Engagement in Care (Implementation Component) — 1; 1 Participants

Primary: Rabies Neutralizing Antibody Titers — 8.48 IU/ml

Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants

Primary: T Cell Activation — 1.8; 1.3 percentage of CD4+ T cells

Primary: Outcome 1: Serial HIV-1 RNA Levels in Breastmilk. — 2.74; 2.03; 1.70; 1.70 Log10 Viral load copies/ml

Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 3; 2; 2; 3 Participants

Primary: Sero-response to Hepatitis B Surface Antigen — 60; 73.2; 75.4 percentage of participants who resonded — p=0.0440

Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened

Primary: The Rate of Related Adverse Events in Subjects Who Began cART During Acute or Early HIV-1 Infection. — 0; 0 Related Adverse Events

Primary: Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants — 0.65; 0.50; 1.99 events per 100 person years — p=<0.001

Primary: The Number of Participants Who Had at Least One Adverse Event (AE) — 118; 11; 8; 0 Participants

Primary: Number of Participants With Moderate or Greater Reactogenicity (i.e., Solicited Adverse Events) — 2; 4 Participants

Primary: Adjusted Odds Ratio of Level of Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS) Associated With Odds of HIV Viral Suppression at All Study Visits — 73.5…

Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale

Primary: Prevalence of HIV Infection — 6 Participants